GET DAILY SIGNALSQuantum-Si (QSI) Analyst Targets Suggest +39% Upside, But the Path Is Far From Certain
Key Takeaways
- The $2.30 central target is the arithmetic mean of three verified analyst price targets reviewed for this article — H.C. Wainwright at $4.00, Alliance Global Partners at $1.90, and Canaccord Genuity at $1.00.
- With Quantum-Si Incorporated (QSI) recently trading near $1.65, reaching $2.30 would require a gain of roughly 39%, a substantial move.
- Individual targets span a very wide range, from $1.00 to $4.00, reflecting deep disagreement about the company's commercial outlook.
- The bull case rests on the Proteus protein-sequencing platform and an extended cash runway; the bear case centers on a delayed launch, declining revenue, and Nasdaq listing compliance risk.
- Ratings are split between two Buy ratings and one Hold, with no Sell ratings among the three analysts reviewed.
- For more on this company, explore its Major News and Today's Price Move, along with its Forecast and Earnings pages.
Analyst Price Targets and Consensus View
Quantum-Si remains a thinly covered life-sciences name, and the limited number of published targets tells part of the story. I reviewed three current, attributable targets for this piece. H.C. Wainwright's Swayampakula Ramakanth reiterated a Buy rating with a $4.00 target in August 2026. Alliance Global Partners' Scott Henry kept a Buy rating but lowered his target to $1.90 from $2.50 after the second-quarter report. Canaccord Genuity reiterated a Hold rating with a $1.00 target in May 2026.
The arithmetic mean of these three figures comes to about $2.30, which serves as the rounded central target here. It is not an official consensus. The $1.00-to-$4.00 spread is unusually wide and signals that analysts are working from very different assumptions about whether Quantum-Si can turn its technology into commercial results. The two Buy-rated views focus on upside from the Proteus platform, while the Hold rating reflects caution around near-term commercialization and revenue.
Current Market Position and Path Toward the Target
Quantum-Si Incorporated (QSI) shares recently closed near $1.65 after a sharp rally that moved the stock well above its 52-week low of roughly $0.69. A move to $2.30 would imply upside of about 39%, which qualifies as substantial given the company's limited revenue and ongoing losses.
Progress toward that level would likely hinge on the Proteus platform, the company's next-generation single-molecule protein-sequencing technology. Management has outlined a controlled-to-commercial launch transition, yet the rollout has faced delays, pushing back the timeline for meaningful recurring revenue. Revenue stayed minimal at roughly $344,000 in the most recent quarter against a much larger cost base, so any sustained re-rating would need visible commercial milestones rather than valuation expansion alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
The main support comes from the Proteus platform and the broader proteomics opportunity. Quantum-Si is working to make protein sequencing more accessible and affordable, and successful demonstrations, including progress toward identifying all 20 standard amino acids, have sparked sharp rallies at times. Management has focused on cash conservation, including a workforce reduction, and has pointed to an extended runway into late 2028, which eases near-term financing concerns.
Analyst backing adds another layer. Two of the three tracked analysts maintain Buy ratings with targets well above the current price. If Proteus secures customer traction or if new partnerships or placements are announced, sentiment could shift quickly given the stock's high beta and news-driven trading patterns.
What Could Prevent the Target From Being Reached
The risks remain significant. Revenue has fallen sharply year over year, and the company continues to post deep losses on both a GAAP and operating basis. The delayed Proteus launch pushes back customer evaluations and consumables revenue, which means losses could continue for some time. Quantum-Si is not involved in quantum computing, and some of the recent share-price strength appears linked to investor confusion around that theme, which could reverse.
Nasdaq minimum bid-price compliance also poses a risk; failure to regain compliance could lead to delisting or actions such as a reverse stock split. Any future capital raise or secondary offering would likely weigh on the share price, and insider selling has been reported. Any of these factors could keep the stock well below $2.30.
Technical Levels and Market Structure
The stock's long-term range shows extreme volatility. Shares have moved from about $0.69 on the low end to the low $2.30s on the high end over the past year. The recent advance has brought the stock back toward the $2.00 psychological zone, with prior highs in the $2.32-to-$2.42 area serving as the next notable resistance. On the downside, the area near the last closing level around $1.46 and the $1.00 mark offer reference support zones. Given the high volatility, these levels should be treated as broad zones rather than exact turning points.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the three firms do not publish identical timelines and one target predates the others. Investors should watch the next quarterly earnings report, expected in early November 2026, along with any updates on Proteus launch timing, customer placements, and consumables revenue. Cost discipline and cash-burn figures will matter, as will any news on Nasdaq compliance or future financing. Changes to analyst targets or ratings, especially from the two Buy-rated firms, would also serve as important signals.
Using AI Daily Buy/Sell Signals in My Research
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Quantum-Si, these tools help surface opportunities, track positions, and identify changing trends more efficiently than manual chart review alone. Traders seeking a data-driven edge may find value in how these signals complement their own research process.
Final Assessment
The $2.30 figure represents a calculated average of three analyst targets, not a prediction of future performance. Reaching it would require a roughly 39% advance from around $1.65, a substantial move that depends largely on the Proteus platform achieving real commercial traction. The wide $1.00-to-$4.00 target range highlights genuine analyst disagreement on that outcome. Support comes from the platform's potential, an extended cash runway, and two Buy ratings; obstacles include the delayed launch, shrinking revenue, persistent losses, and listing-compliance risk. Investors should monitor Proteus milestones, the upcoming earnings report, and any analyst or financing developments before forming conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
QSI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for QSI turned positive on October 27, 2026. Looking at past instances where QSI's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on QSI as a result. In 78 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
QSI moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 98 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for QSI moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 26 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.004) is normal, around the industry mean (3.837). P/E Ratio (-3.587) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement